WAM
CYT

Wolverine Asset Management’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Wolverine Asset Management’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-570
Closed -$1.73K – 1966
2023
Q4 		$1.73K Hold
570
– – ﹤0.01% 1569
2023
Q3 		$1.62K Buy
+570
New +$1.57K ﹤0.01% 1663

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Wolverine Asset Management's CYT Position: Q1 2024 in Review

Wolverine Asset Management sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 570 shares — an estimated $1.73K sold.

Wolverine Asset Management first reported a position in CYT in Q3 2023 and held it in 2 quarters. The position peaked at $1.73K in Q4 2023. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • Wolverine Asset Management reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Wolverine Asset Management sold 570 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.73K.
  • Wolverine Asset Management first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
  • Wolverine Asset Management's Cyteir Therapeutics, Inc. Common Stock position peaked at $1.73K in Q4 2023.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Wolverine Asset Management's 13F filing for Q1 2024, filed 13 May 2024.